Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

IntroductionThe treatment of diabetes has a significant impact on the pathogenesis of non-alcoholic fatty liver disease (NAFLD). We compared the effectiveness of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, and pioglitazone for the treatment of NAFLD patients with type 2 diab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ open diabetes research & care 2021-02, Vol.9 (1), p.e001990, Article 001990
Hauptverfasser:	Yoneda, Masato, Honda, Yasushi, Ogawa, Yuji, Kessoku, Takaomi, Kobayashi, Takashi, Imajo, Kento, Ozaki, Anna, Nogami, Asako, Taguri, Masataka, Yamanaka, Takeharu, Kirikoshi, Hiroyuki, Iwasaki, Tomoyuki, Kurihashi, Takeo, Saito, Satoru, Nakajima, Atsushi
Format:	Artikel
Sprache:	eng
Schlagworte:	Benzhydryl Compounds Cholesterol Diabetes Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Drug dosages Drug therapy Endocrinology & Metabolism Glucose Glucosides Humans Insulin resistance Japan Laboratories Life Sciences & Biomedicine Liver diseases Metabolic syndrome Metabolism Non-alcoholic Fatty Liver Disease - diagnostic imaging Non-alcoholic Fatty Liver Disease - drug therapy Patients Pioglitazone - therapeutic use Prospective Studies Registration Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!